Viewing Study NCT05907057

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2026-05-30 @ 1:13 AM
Study NCT ID: NCT05907057
Status: RECRUITING
Last Update Posted: 2025-04-11
First Post: 2023-06-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Sponsor: Servier Affaires Médicales
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia (AML) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None IDH1 Mutation AML View